Financial Data and Key Metrics Changes - The company reported second quarter organic sales growth of 0.6% despite an uncertain macro environment, with adjusted EPS growing 5% to $0.80, slightly ahead of guidance [6][10] - Adjusted EBITDA margin expanded by 30 basis points to 17.2%, driven by favorable mix, productivity initiatives, and disciplined discretionary spending [6][10] - For the first half of the year, organic sales grew about 1%, with expectations for a similar demand environment in the second half [7][10] Business Line Data and Key Metrics Changes - The Color Additives and Inks segment saw adjusted EBITDA grow 4% on 2% lower organic sales, with weaker demand in consumer and transportation markets offset by strong growth in healthcare [16] - The Specialty Engineered Materials segment grew organic sales by 6%, driven by strong demand in defense and healthcare, with healthcare growing double digits [17][18] - Packaging Materials, the segment's largest end market, experienced muted sales growth, particularly in EMEA, despite overall EBITDA margin expansion of 100 basis points [16][20] Market Data and Key Metrics Changes - In the U.S. and Canada, sales increased 1% year over year, led by healthcare and defense, offsetting weaker demand in consumer and transportation markets [19] - EMEA sales were down slightly, with robust healthcare and defense sales but muted packaging sales [20] - Asia delivered 3% organic growth, marking the fifth consecutive quarter of growth, with strength in healthcare and transportation [20] Company Strategy and Development Direction - The company aims to evolve from a specialty formulator to an innovator of material solutions, with a focus on strategic structural changes in R&D to enhance product differentiation [9][11] - The operational playbook is designed to realize approximately $40 million in benefits for 2025, with a focus on sourcing, Lean Six Sigma, and manufacturing optimization [8][10] - The company is prioritizing investments in growth vectors, particularly in healthcare and defense, which are expected to drive future growth [12][18] Management's Comments on Operating Environment and Future Outlook - Management noted that market trends are not improving, with customers remaining in a wait-and-see mode, particularly in consumer markets [7][10] - The company expects Q3 to continue the trends observed in Q2, with consumer weakness anticipated to persist [7][45] - Despite challenges, management remains optimistic about strong demand in defense and healthcare, which are seen as bright spots for the business [7][18] Other Important Information - The company has already realized $17 million of the $40 million benefits targeted for 2025, with the remaining expected in the second half [8] - The company is on track to reduce total debt by $100 million to $200 million by year-end, having repaid $50 million in the second quarter [11][22] Q&A Session Summary Question: Is there any pre-buying activity affecting sales? - Management indicated no significant pre-buying activity has been observed, as customers are managing inventory tightly in the current uncertain demand environment [25][26] Question: What is the outlook for raw material inflation? - The company expects raw material inflation to remain at 1% to 2% for the year, with some fluctuations in specific materials [28][29] Question: What is the outlook for volume in the second half? - Management anticipates a continuation of trends from the first half, with consumer markets expected to decline and packaging to grow slightly [35][36] Question: How has consumer weakness evolved? - Consumer sales were flat in Q1 and down 8% in Q2, with significant weakness noted in the U.S. and Canada [44][45] Question: What is the impact of planned maintenance on EBITDA? - The planned maintenance in the SEM segment impacted EBITDA by approximately $3 million in Q2, but margins are expected to expand in the second half [46][80] Question: Are customers pressuring for tariff cost absorption? - Management acknowledged some pressure on pricing due to increased tariffs, but they are working with suppliers and customers to manage costs [50][51] Question: Can you provide context on healthcare growth? - Healthcare has shown strong growth, particularly in medical devices and drug delivery, with a positive outlook for continued demand [62][63] Question: What are the trends in key markets in China? - The color business in China is under pressure due to government policies, but growth is expected in the SEM side related to high-performance computing [66][68]

Q2 2025 Performance - Sales reached $867 million, reflecting a 2% increase compared to Q2 2024 [9] - Adjusted EBITDA was $149 million, a 3.9% increase year-over-year [9] - Adjusted EPS increased by 5.3% to $0.80 [9] - Adjusted EBITDA margin was 17.2% [10] Segment Performance - Color, Additives & Inks sales were $539 million, a 1% decrease, but adjusted EBITDA margin expanded by 100 bps to 20.9% [20] - Specialty Engineered Materials sales increased by 7% to $330 million, but adjusted EBITDA margin decreased to 19% [23] Regional Growth - Organic revenue growth by region: US & Canada +1%, Europe, Middle East & Africa -1%, Asia +3%, Latin America +6% [25] Full Year 2025 Guidance - Adjusted EBITDA is projected to be between $545 million and $560 million, representing a 4% to 6% growth excluding foreign exchange impact [28] - Adjusted EPS is expected to be between $2.77 and $2.87 for the full year [28] - Free Cash Flow is expected to be $190 million to $210 million for FY 2025 [16] Productivity and Debt Reduction - $40 million of full year YoY productivity benefits more than offset inflation & investments in growth vectors [14] - $50 million debt reduction in Q2; expect $100 million to $200 million total debt reduction by year end [16]

Second quarter sales of $867 million reflect 2% growth over the prior year quarter and includes a favorable impact of 1% from foreign exchange Second quarter GAAP EPS of $0.57 compared to $0.36 in the prior year quarter Second quarter adjusted EPS of $0.80 exceeds previous guidance of $0.79; represents 5% growth over the prior year quarter and includes a favorable impact of $0.01 attributable to foreign exchange 2025 full-year adjusted EPS guidance range narrowed to $2.77 to $2.87 from previous guidance of ...

Core Insights - Huntsman reported revenue of $1.46 billion for the quarter ended June 2025, a decrease of 7.4% year-over-year, with an EPS of -$0.20 compared to $0.14 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $1.48 billion by 1.26%, and the EPS was 33.33% below the consensus estimate of -$0.15 [1] Financial Performance - Huntsman's stock has returned -12.5% over the past month, contrasting with the Zacks S&P 500 composite's +2.7% change, and currently holds a Zacks Rank 5 (Strong Sell) [3] - Sales volume for Polyurethanes decreased by 2%, while the average estimate was a decline of 5.4% [4] - Revenue from Polyurethanes was reported at $932 million, which is lower than the average estimate of $942.75 million, reflecting a year-over-year change of -6.9% [4] - Revenue from Advanced Materials was $264 million, slightly below the estimated $267.32 million, marking a -5.4% change year-over-year [4] - Performance Products revenue was reported at $270 million, compared to the average estimate of $292.22 million, indicating a -9.7% year-over-year change [4]

Core Points - Huntsman Corporation declared a cash dividend of $0.25 per share on its common stock, payable on September 30, 2025, to stockholders of record as of September 15, 2025 [1] - Huntsman Corporation reported approximately $6 billion in revenues for 2024, indicating a strong market presence in the specialty chemicals sector [2] - The company operates over 60 manufacturing, R&D, and operations facilities across approximately 25 countries, employing around 6,300 associates [2]

Core Insights - Huntsman Corporation reported a significant net loss of $158 million for Q2 2025, compared to a net income of $22 million in Q2 2024, indicating a challenging financial environment [2][10] - The company's revenues decreased to $1,458 million in Q2 2025 from $1,574 million in Q2 2024, reflecting a 7% decline [2][10] - Adjusted EBITDA fell to $74 million in Q2 2025, down from $131 million in the same period last year, highlighting operational difficulties [2][10] Financial Performance - Revenues for the first half of 2025 totaled $2,868 million, down from $3,044 million in the first half of 2024 [13] - The diluted loss per share for Q2 2025 was $0.92, compared to a diluted income per share of $0.13 in Q2 2024 [10][13] - Free cash flow from continuing operations improved to $55 million in Q2 2025, up from $5 million in Q2 2024 [7][10] Segment Analysis - The Polyurethanes segment saw a revenue decrease of 7% year-over-year, primarily due to lower average selling prices and sales volumes [4][13] - Performance Products segment revenues declined by 10%, driven by lower sales volumes despite stable average selling prices [5][13] - Advanced Materials segment revenues fell by 5%, attributed to lower average selling prices and reduced demand in coatings and aerospace markets [6][13] Cost Management and Restructuring - The company is implementing cost reduction measures, including the closure of its European Maleic Anhydride facility and a global workforce reduction of nearly 10% [3] - Restructuring efforts initiated at the end of 2024 have expanded in 2025, reflecting the need to adapt to current market conditions [3] Liquidity and Capital Resources - As of June 30, 2025, Huntsman had approximately $1.3 billion in combined cash and unused borrowing capacity [7] - Capital expenditures for Q2 2025 were $37 million, down from $50 million in Q2 2024, with expectations to spend between $180 million to $190 million for the full year [8][10] Tax and Effective Rates - The effective tax rate for Q2 2025 was reported at -5%, indicating a unique tax situation for the period [9]

Core Insights - Element Solutions (ESI) reported revenue of $625.2 million for the quarter ended June 2025, marking a year-over-year increase of 2% and a surprise of +3.35% over the Zacks Consensus Estimate of $604.97 million [1] - The earnings per share (EPS) for the same period was $0.37, compared to $0.36 a year ago, resulting in an EPS surprise of +2.78% against the consensus estimate of $0.36 [1] Financial Performance Metrics - Net Sales in the Industrial & Specialty segment were $185.8 million, exceeding the average estimate of $178.67 million by three analysts, but reflecting a year-over-year decline of -15.9% [4] - Net Sales in the Electronics segment reached $439.4 million, surpassing the average estimate of $426.27 million, with a year-over-year increase of +12.2% [4] - Adjusted EBITDA for the Industrial & Specialty segment was $39.5 million, above the average estimate of $34 million [4] - Adjusted EBITDA for the Electronics segment was $96.5 million, slightly below the average estimate of $97.03 million [4] Stock Performance - Shares of Element Solutions have returned +2.6% over the past month, compared to a +3.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Financial Performance - Hawkins' 2025 revenue reached $9744 million[10] - The company's 5-year EPS CAGR is 25%[10] - Net income in fiscal year 2025 was $843 million, with a 24% CAGR[67] - Adjusted EBITDA in fiscal year 2025 was $1675 million, with a 21% CAGR[69] - Diluted EPS in fiscal year 2025 was $403, with a 25% CAGR[74] - Q1 Fiscal Year 2026 revenue reached a record $2933 million, a 15% increase year-over-year[81] - Q1 Fiscal Year 2026 Adjusted EBITDA reached a record $574 million, a 13% increase year-over-year[81] Business Segments - Water Treatment accounted for 46% of revenue, totaling $4465 million[15] - Food & Health Sciences accounted for 33% of revenue, totaling $3225 million[15] - Industrial Solutions accounted for 21% of revenue, totaling $2054 million[15] Capital Allocation - The company has consistently returned capital to shareholders through dividends and share repurchases[32] - Hawkins has a track record of 40 consecutive years of cash dividends[33]

Financial Data and Key Metrics Changes - Q3 sales were $463 million, down 15% year over year, including a $53 million impact from portfolio optimization, with organic sales declining 5% primarily due to lower volumes [14][8] - Adjusted EBITDA was $113 million, down 19% year over year or 10% excluding portfolio actions, with adjusted EBITDA margins at 24.4%, down 120 basis points [15][8] - Adjusted EPS, excluding acquisition amortization, was $1.04, down 30% from the prior year, with a noncash goodwill impairment of $6 million recorded [16][8] Business Line Data and Key Metrics Changes - Life Sciences sales were $162 million, down 17% year over year, primarily due to portfolio optimization initiatives, with organic sales declining just 1% [18][9] - Personal Care sales were $147 million, down 16% year over year, driven by portfolio optimization actions, with organic sales declining 6% [24][9] - Specialty Additives sales declined 13% to $131 million, with organic sales and volumes both down 11% [29][9] Market Data and Key Metrics Changes - Life Sciences maintained strong margins of 33% for the second consecutive quarter despite a mixed demand environment [9][10] - Intermediates faced a challenging supply-demand landscape, particularly in Europe, with sales down to $33 million from $36 million year over year [21][9] - Personal Care showed early signs of recovery, particularly in biofunctional actives, with sales up double digits supported by a robust commercial pipeline [25][9] Company Strategy and Development Direction - The company completed its portfolio optimization and restructuring program ahead of schedule, focusing on cost savings and operational efficiency [12][11] - The strategic imperative is to drive consistent operations at higher utilization rates while balancing cost actions with strategic reinvestment [33][12] - The company aims to expand its reach in underpenetrated markets and drive differentiation through innovation [12][11] Management's Comments on Operating Environment and Future Outlook - Management noted that while the external environment remains uncertain, the company is executing with discipline and focus, positioning for long-term resilient performance [12][11] - The company expects full-year fiscal 2025 sales of approximately $1.825 billion to $1.85 billion and adjusted EBITDA in the range of $400 million to $410 million [45][12] - Management highlighted that demand patterns remain mixed, with pharma steady and personal care showing encouraging signs of recovery [42][12] Other Important Information - The company generated nearly 100% free cash flow conversion in the quarter, demonstrating the strength of its underlying business [15][8] - Liquidity at quarter end was over $800 million, with net leverage at 2.9 times, providing flexibility for strategic investments [17][8] - The company is actively monitoring tariff-related uncertainties but does not anticipate a material direct impact on fiscal year 2025 results [43][12] Q&A Session Summary Question: Insights on fiscal year 2026 outlook and demand recovery - Management indicated that while they are not providing guidance for fiscal year 2026, they see stable demand in personal care and pharma, with potential upside in specialty additives depending on market conditions [50][51] Question: Clarification on cost savings from restructuring and network optimization - Management confirmed that incremental savings in fiscal year 2026 should be in the range of $55 million to $60 million year over year, with restructuring actions completed [74][75] Question: Stability in personal care markets and customer feedback - Management noted stability in mass brands and some variability in the prestige segment, with positive traction observed in Asia and Europe [66][67]

earnings conference call third quarter fiscal 2025 July 30, 2025 O Regulation G: Adjusted Results the information presented herein regarding certain uncudited adjusted results does not conform to generally accepted accounting principles in the United Srates (U.S. GAAP) should not be construed as an affernative to the reported results determined in accordance with U.S. GAAP. Ashland has included this non-GAAP information to assis in understranding the operating performance of the company ond its reportable s ...